Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Laboratory Corp American Holdings (NY: LH )

247.29 +1.00 (+0.41%)
Streaming Delayed Price Updated: 3:12 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Laboratory Corp American Holdings

< Previous 1 2 3 4 5 6 Next >
NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. 
Via StockStory
Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook
Labcorp's Q4 EPS of $3.45 topped estimates, with sales rising 9.8% to $3.33 billion. 2025 guidance points to continued growth in diagnostics and biopharma. 
Via Benzinga
Labcorp (NYSE:LH) Surprises With Q4 Sales, Full-Year Outlook Slightly Exceeds Expectations
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 9.8% year on year to $3.33 billion. The company’s full-year revenue... 
Via StockStory
Earnings Scheduled For February 6, 2025
Via Benzinga
Labcorp (LH) Reports Earnings Tomorrow: What To Expect
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) will be reporting earnings tomorrow before the bell. Here’s what to look for. 
Via StockStory
Beyond The Numbers: 6 Analysts Discuss Labcorp Holdings Stock
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Labcorp Holdings Stock
Via Benzinga
Analyst Expectations For Labcorp Holdings's Future
Via Benzinga
Jim Cramer Says Lazard Is 'Really Inexpensive,' Recommends Buying This Tech Stock
Via Benzinga
Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization. 
Via Benzinga
Topics Government
Exposures Political
Expert Outlook: Labcorp Holdings Through The Eyes Of 12 Analysts
Via Benzinga
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
LabCorp Q3 2024 EPS beats expectations at $3.50, with 7.4% revenue growth to $3.28B. Adjusted EPS guidance revised due to weather. 
Via Benzinga
Topics Earnings
Exposures Financial
Analyst Ratings For Labcorp Holdings
Via Benzinga
Analyst Expectations For Labcorp Holdings's Future
Via Benzinga
LabCorp Analysts Boost Their Forecasts After Better-Than-Expected Earnings
Via Benzinga
Labcorp Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
Via Benzinga
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Labcorp Holdings
Via Benzinga
Analyst Ratings For Laboratory Corp
Via Benzinga
Laboratory Corp's Ex-Dividend Date Is Monday, Here's What You Need To Know
Via Benzinga
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024... 
Via Benzinga
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions. 
Via Talk Markets
Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
Labcorp beats Q1 sales estimates, driven by organic growth and acquisitions. Revised 2024 guidance projects higher EPS and sales growth. The acquisition of Invitae is expected to bolster Labcorp's... 
Via Benzinga
LH Stock Earnings: Laboratory Corp Beats EPS, Beats Revenue for Q1 2024
LH stock results show that Laboratory Corp beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Labcorp Expands Diagnostic Reach With Strategic Deal For Select Assets Of BioReference Health
Labcorp acquires certain operations of Opko Health subsidiary BioReference Health. The assets Labcorp is acquiring generate about $100 million in annual revenue, with the transaction valued at $237.5... 
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection. 
Via Benzinga
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records. 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.